Related Experiment Video
Updated: May 23, 2026
11:07
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
Published on: April 14, 2022
Myasthenia gravis from Thomas Willis to the present
1Department of Pediatrics, Neurology, Anatomy and Cell Biology, Roy J. and Lucille A Carver College of Medicine, University of Iowa, 200 Hawkins Drive, Iowa City, Iowa 52242-1083, United States of America.
Neurosciences (Riyadh, Saudi Arabia)
|April 5, 2012
Summary
This review covers myasthenia gravis, detailing its immune and non-immune forms, pathogenesis, diagnosis, and treatments. It explores the thymus
Area of Science:
- Neurology
- Immunology
- Medical History
Background:
- Myasthenia gravis (MG) is a rare, chronic autoimmune neuromuscular disease.
- Understanding MG has evolved significantly over time.
- Both immune-mediated and non-immune-mediated forms exist.
Purpose of the Study:
- To provide a comprehensive review of myasthenia gravis.
- To discuss the historical development of knowledge regarding MG.
- To cover pathogenesis, diagnosis, and treatment strategies.
Main Methods:
- Literature review of historical and current research on myasthenia gravis.
- Analysis of clinical profiles and diagnostic yields.
- Examination of therapeutic modalities and future strategies.
Main Results:
- Detailed review of the clinical presentations of immune and non-immune MG.
- Explanation of current theories on MG pathogenesis.
- Comparison of diagnostic test yields and treatment efficacy.
Conclusions:
- Myasthenia gravis knowledge has advanced significantly.
- Current understanding encompasses pathogenesis, diagnosis, and diverse treatments.
- The role of the thymus and thymectomy is crucial in MG management.
Related Concept Videos
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...